KR102359257B1 - 망막 질환의 치료 방법 - Google Patents

망막 질환의 치료 방법 Download PDF

Info

Publication number
KR102359257B1
KR102359257B1 KR1020177021263A KR20177021263A KR102359257B1 KR 102359257 B1 KR102359257 B1 KR 102359257B1 KR 1020177021263 A KR1020177021263 A KR 1020177021263A KR 20177021263 A KR20177021263 A KR 20177021263A KR 102359257 B1 KR102359257 B1 KR 102359257B1
Authority
KR
South Korea
Prior art keywords
cells
cell
pharmaceutical composition
delete delete
rpe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177021263A
Other languages
English (en)
Korean (ko)
Other versions
KR20170120583A (ko
Inventor
에얄 바닌
벤자민 에이탄 레우비노프
오스나트 보하나-카쉬탄
니르 네체르
찰스 셰라드 어빙
Original Assignee
셀 큐어 뉴로사이언시스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56284392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102359257(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 셀 큐어 뉴로사이언시스 리미티드 filed Critical 셀 큐어 뉴로사이언시스 리미티드
Priority to KR1020227003550A priority Critical patent/KR102514912B1/ko
Publication of KR20170120583A publication Critical patent/KR20170120583A/ko
Application granted granted Critical
Publication of KR102359257B1 publication Critical patent/KR102359257B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00727—Apparatus for retinal reattachment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • Y10S514/912—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020177021263A 2014-12-30 2015-04-30 망막 질환의 치료 방법 Active KR102359257B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227003550A KR102514912B1 (ko) 2014-12-30 2015-04-30 망막 질환의 치료 방법

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462097753P 2014-12-30 2014-12-30
US62/097,753 2014-12-30
US201562116980P 2015-02-17 2015-02-17
US201562116972P 2015-02-17 2015-02-17
US62/116,980 2015-02-17
US62/116,972 2015-02-17
PCT/IL2015/050456 WO2016108219A1 (en) 2014-12-30 2015-04-30 Methods of treating retinal diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003550A Division KR102514912B1 (ko) 2014-12-30 2015-04-30 망막 질환의 치료 방법

Publications (2)

Publication Number Publication Date
KR20170120583A KR20170120583A (ko) 2017-10-31
KR102359257B1 true KR102359257B1 (ko) 2022-02-07

Family

ID=56284392

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177021263A Active KR102359257B1 (ko) 2014-12-30 2015-04-30 망막 질환의 치료 방법
KR1020227003550A Active KR102514912B1 (ko) 2014-12-30 2015-04-30 망막 질환의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227003550A Active KR102514912B1 (ko) 2014-12-30 2015-04-30 망막 질환의 치료 방법

Country Status (18)

Country Link
US (2) US20180008458A1 (enExample)
EP (1) EP3240612B1 (enExample)
JP (4) JP2018501281A (enExample)
KR (2) KR102359257B1 (enExample)
CN (3) CN107427534A (enExample)
AU (3) AU2015373111B2 (enExample)
BR (1) BR112017014332A2 (enExample)
CA (2) CA3175175A1 (enExample)
DK (1) DK3240612T3 (enExample)
EA (1) EA201791518A1 (enExample)
ES (1) ES2843626T3 (enExample)
HK (1) HK1246179A1 (enExample)
IL (1) IL253244B2 (enExample)
MX (1) MX2017008818A (enExample)
PH (1) PH12017501217A1 (enExample)
SG (1) SG11201705378RA (enExample)
WO (1) WO2016108219A1 (enExample)
ZA (1) ZA201704359B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
SG11201705378RA (en) * 2014-12-30 2017-08-30 Cell Cure Neurosciences Ltd Methods of treating retinal diseases
CA2972580A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
EP3674397A1 (en) 2014-12-30 2020-07-01 Cell Cure Neurosciences Ltd. Rpe cell populations and methods of generating same
EP3862425A1 (en) 2015-07-29 2021-08-11 Hadasit Medical Research Services and Development Ltd. Large scale production of retinal pigment epithelial cells
EA201890424A1 (ru) 2015-08-05 2018-06-29 Селл Кьюр Нейросайансес Лтд. Получение клеток пигментного эпителия сетчатки
CA2993910A1 (en) * 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
CN118021843A (zh) 2017-03-16 2024-05-14 谱系细胞疗法公司 用于测量视网膜疾病疗法的疗效的方法
WO2019028088A1 (en) 2017-07-31 2019-02-07 Biotime, Inc. COMPOSITIONS AND METHODS FOR RESTORING OR PREVENTING LOSS OF VISION CAUSED BY TRAUMATIC DISEASE OR INJURY
AU2018393494A1 (en) * 2017-12-29 2020-07-09 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
US12110503B2 (en) 2018-04-20 2024-10-08 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
CN108795864B (zh) * 2018-05-24 2021-08-24 中山大学中山眼科中心 一种利用人诱导多能干细胞获得富含视锥及视杆细胞的类视网膜组织的方法
US10264436B1 (en) * 2018-05-29 2019-04-16 Link Labs, Inc. BLE networking systems and methods providing central and peripheral role reversal with independent peripheral network connectivity
WO2020047476A1 (en) * 2018-08-31 2020-03-05 University Of Florida Research Foundation, Incorporated Adeno-associated viral vectors for the treatment of best disease
US20220259558A1 (en) * 2019-05-15 2022-08-18 Novo Nordisk A/S Methods for obtaining eye field progenitor cells from human pluripotent stem cells
CA3184790A1 (en) * 2020-05-25 2021-12-02 Lineage Cell Therapeutics, Inc. Methods and compositions for treating retinal diseases and conditions
EP3964227A1 (en) * 2020-09-08 2022-03-09 Curebiotec GmbH Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
KR20230061502A (ko) * 2020-09-03 2023-05-08 큐어바이오텍 게엠베하 황반 변성 또는 맥락막 혈관신생 치료에 사용하기 위한 색소 상피-유래 인자(ｐｅｄｆ)
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115137553A (zh) * 2022-07-11 2022-10-04 上海市同济医院 一种免造孔视网膜下液排出装置
CN115212233B (zh) * 2022-08-26 2024-05-28 北京市眼科研究所 用于治疗视网膜相关疾病的组合物、试剂盒及其应用
WO2024110625A1 (en) * 2022-11-24 2024-05-30 Universität Bern Cralbp based therapeutics for retinal disorders
KR102531735B1 (ko) * 2022-12-27 2023-05-12 주식회사 셀리코 초소형 자극기 및 이의 제조방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CN101688178B (zh) 2007-04-18 2013-12-04 哈达锡特医学研究服务及发展有限公司 干细胞衍生的视网膜色素上皮细胞
IL292561A (en) * 2007-10-12 2022-06-01 Astellas Inst For Regenerative Medicine Improved methods of rpe cell production and rpe cell preparations
KR101025880B1 (ko) * 2008-10-23 2011-03-30 공희숙 성체 줄기세포를 이용한 인슐린 분비세포로의 분화 유도방법
WO2011063005A2 (en) * 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
LT2780022T (lt) * 2011-11-14 2019-07-10 Astellas Institute For Regenerative Medicine Žmogaus rpe ląstelių farmaciniai preparatai ir jų panaudojimas
US9850463B2 (en) * 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
US20150112282A1 (en) * 2012-04-09 2015-04-23 Industry-Academic Cooperation Foundation, Yonsei University Hollow microneedle and subretinal syringe for subretinal injection or extraction
WO2014121077A2 (en) * 2013-02-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
JP2017504311A (ja) * 2013-12-11 2017-02-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 網膜色素上皮細胞を生成する方法
EP3674397A1 (en) 2014-12-30 2020-07-01 Cell Cure Neurosciences Ltd. Rpe cell populations and methods of generating same
SG11201705378RA (en) * 2014-12-30 2017-08-30 Cell Cure Neurosciences Ltd Methods of treating retinal diseases
CA2972580A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
KR101982801B1 (ko) * 2015-10-28 2019-05-30 서울대학교 산학협력단 망막색소상피 분화 유도용 조성물

Also Published As

Publication number Publication date
AU2021229196A1 (en) 2021-10-07
AU2015373111A1 (en) 2017-07-13
WO2016108219A1 (en) 2016-07-07
KR20220020422A (ko) 2022-02-18
HK1246179A1 (zh) 2018-09-07
PH12017501217A1 (en) 2018-01-29
JP2018501281A (ja) 2018-01-18
JP2022125160A (ja) 2022-08-26
CA2972700A1 (en) 2016-07-07
AU2023255009A1 (en) 2023-11-16
IL253244B2 (en) 2023-09-01
US20230028133A1 (en) 2023-01-26
ZA201704359B (en) 2018-08-29
AU2015373111B2 (en) 2021-06-24
SG11201705378RA (en) 2017-08-30
DK3240612T3 (da) 2021-01-18
MX2017008818A (es) 2018-03-14
ES2843626T3 (es) 2021-07-19
IL253244A0 (en) 2017-08-31
IL253244B1 (en) 2023-05-01
EP3240612B1 (en) 2020-12-23
BR112017014332A2 (pt) 2018-01-02
CN114469998A (zh) 2022-05-13
US20180008458A1 (en) 2018-01-11
EA201791518A1 (ru) 2017-10-31
EP3240612A1 (en) 2017-11-08
KR102514912B1 (ko) 2023-03-27
JP2024023611A (ja) 2024-02-21
JP2020143137A (ja) 2020-09-10
EP3240612A4 (en) 2018-06-13
CN107427534A (zh) 2017-12-01
CA3175175A1 (en) 2016-07-07
CN114533761A (zh) 2022-05-27
KR20170120583A (ko) 2017-10-31

Similar Documents

Publication Publication Date Title
US20230028133A1 (en) Methods of treating retinal diseases
AU2015373050B2 (en) RPE cell populations and methods of generating same
JP7723482B2 (ja) 網膜色素上皮細胞集団の評価法
AU2018234933B2 (en) Methods for measuring therapeutic effects of retinal disease therapies
HK40066083A (en) Methods of treating retinal diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170728

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200429

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210428

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20211029

GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220128

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220128

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220203

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20241224

Start annual number: 4

End annual number: 4